Anthem Biosciences quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	418	540	−22.6%
EBITDA	151	191	−21.4%
EBITDA margin	36.0%	35.5%	+0.5 pts
Profit before tax	145	186	−22.4%
Net profit	120	136	−11.7%
EPS	₹2.13	₹2.43	−12.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025

Expenses
	418	611	423	550	540
	24.9	51.2	33.5	48.2	22.8
	443	662	457	598	563
	149	165	185	201	162
	−2.4	50.3	−42.3	22.1	68.7
	78.8	72.5	70.5	67.7	72.0
	0.9	1.9	0.4	3.0	1.6
	30.0	39.6	34.5	33.5	26.4
	42.6	55.8	52.9	41.0	45.8
	299	385	301	369	377
	151	267	157	218	191
	121	228	123	184	165
Profit
	145	277	156	230	186
	0.0	1.0	−25.4	0.0	0.0
	145	278	130	230	186
	34.7	89.7	37.8	63.8	50.1
	−10.1	−1.5	−0.1	−7.6	0.4
	24.6	88.2	37.7	56.2	50.5
	120	190	92.8	173	136
	120	190	92.8	173	136
	0.9	−0.8	−0.8	−1.5	1.5
	121	189	92.0	172	137
	—	—	92.8	173	136
Per share
	₹2.13	₹3.38	₹1.65	₹3.09	₹2.43
	₹2.11	₹3.34	₹1.64	₹3.06	₹2.42
Other comprehensive income — detail
	0.9	−0.8	−0.8	−1.5	1.5
	0.9	−0.8	−1.1	−1.5	1.5
	0.2	0.0	−0.3	0.0	0.0
	0.3	—	—	—	—
	0.1	—	0.0	—	—
	—	—	92.8	—	—
Per share — as-filed variants
	₹2.13	₹3.38	₹1.65	₹3.09	₹2.43
	₹2.11	₹3.34	₹1.64	₹3.06	₹2.42
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	272	395	281	327	309
	65.0%	64.7%	66.3%	59.4%	57.3%
Adjusted (ex-exceptional items) — derived
	145	277	156	230	186
	0.0	1.0	−25.4	0.0	0.0
	120	189	111	173	136
	₹2.13	₹3.37	₹1.97	₹3.09	₹2.43

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ANTHEM₹832.15

Anthem Biosciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSYNGENE DIVISLAB GLAXO AJANTPHARM IPCALAB ABBOTINDIA MEDANTA GLENMARKMcap ₹46,743 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	540.2	550.0	423.2	610.9	418.2
Other Income	22.8	48.2	33.5	51.2	24.9
Total Income	563.0	598.3	456.7	662.2	443.1
Expenses
+ Cost of Materials Consumed	162.2	201.3	184.9	165.2	148.6
+ Changes in Inventories	68.7	22.1	-42.3	50.3	-2.4
+ Employee Benefit Expense	72.0	67.7	70.5	72.5	78.8
+ Finance Costs	1.6	3.0	0.4	1.9	0.9
+ Depreciation & Amortisation	26.4	33.5	34.5	39.6	30.0
+ Other Expenses	45.8	41.0	52.9	55.8	42.6
Total Expenses	376.8	368.7	300.8	385.2	298.5
EBITDA	191.5	217.9	157.2	267.2	150.6
EBIT	165.0	184.4	122.7	227.6	120.6
Profit
PBT before Exceptional Items	186.2	229.6	155.8	276.9	144.6
+ Exceptional Items	0.0	0.0	-25.4	1.0	0.0
Pretax Income	186.2	229.6	130.5	277.9	144.6
+ Current Tax	50.1	63.8	37.8	89.7	34.7
+ Deferred Tax	0.4	-7.6	-0.1	-1.5	-10.1
Tax Expense	50.5	56.2	37.7	88.2	24.6
Net Income	135.8	173.4	92.8	189.8	119.9
+ Net Income — Continuing Ops	135.8	173.4	92.8	189.8	119.9
+ Other Comprehensive Income	1.5	-1.5	-0.8	-0.8	0.9
Total Comprehensive Income	137.3	171.9	92.0	189.0	120.9
Net Income to Common	135.8	173.4	92.8	—	—
Per Share
Basic EPS	2.43	3.09	1.65	3.38	2.13
Diluted EPS	2.42	3.06	1.64	3.34	2.11
Other Comprehensive Income — detail
+ Other Comprehensive Income	1.5	-1.5	-0.8	-0.8	0.9
+ Items NOT to be Reclassified to P&L	1.5	-1.5	-1.1	-0.8	0.9
+ Tax on Items NOT to be Reclassified	0.0	0.0	-0.3	0.0	0.2
+ Items to be Reclassified to P&L	—	—	—	—	0.3
+ Tax on Items to be Reclassified	—	—	0.0	—	0.1
Comprehensive Income — Owners of Parent	—	—	92.8	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.43	3.09	1.65	3.38	2.13
Diluted EPS — Continuing Operations	2.42	3.06	1.64	3.34	2.11
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	309.3	326.7	280.6	395.5	272.0
Gross Margin %	57.26	59.39	66.30	64.73	65.04
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	186.2	229.6	155.8	276.9	144.6
− Exceptional Items (reconciliation)	0.0	0.0	-25.4	1.0	0.0
Net Income Adj (tax-effected)	135.8	173.4	110.9	189.1	119.9
EPS Adj	2.43	3.09	1.97	3.37	2.13
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	0.05	0.04	0.02	0.02	1.18
Filed Dscr	37.34	27.13	33.79	167.61	28.54
Filed Iscr	116.68	76.75	110.40	147.29	163.93
Paid Up Equity Capital	112.3	112.3	112.3	112.3	112.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Anthem Biosciences Q2 FY27 results date

Anthem Biosciences (NSE: ANTHEM) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 28 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹120 crore, down 11.7% from ₹136 crore in Q1 FY26 and down 36.8% from ₹190 crore in Q4 FY26. Revenue from operations was ₹418 crore, down 22.6% year on year and down 31.5% from the previous quarter.

Board-meeting notice filed: 28 October 2026
Q2 FY26 results (a year earlier): 8 November 2025
Q1 FY27 results (the latest): 21 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 28 Oct
Q1 FY27 net profit: ₹120 Cr−11.7% vs Q1 FY26−36.8% vs Q4 FY26
Q1 FY27 revenue: ₹418 Cr−22.6% vs Q1 FY26−31.5% vs Q4 FY26
Q1 FY27 operating margin: 28.8%−1.7 pts vs Q1 FY26−8.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹173 CrRevenue ₹550 Cr
Q1 FY27 EPS (basic): ₹2.13

Questions

When will Anthem Biosciences announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 28 October 2026). Last year it reported Q2 FY26 on 8 November 2025.

What will Anthem Biosciences' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹173 crore and revenue from operations ₹550 crore. The latest quarter, Q1 FY27, had a net profit of ₹120 crore and revenue of ₹418 crore.

What were Anthem Biosciences' Q1 FY27 results?

Consolidated net profit was ₹120 crore, down 11.7% from ₹136 crore in Q1 FY26 and down 36.8% from ₹190 crore in Q4 FY26. Revenue from operations was ₹418 crore, down 22.6% year on year and down 31.5% from the previous quarter.

How has Anthem Biosciences' profit changed over the last four quarters?

Net profit by quarter: ₹173 crore in Q2 FY26, ₹92.8 crore in Q3 FY26, ₹190 crore in Q4 FY26 and ₹120 crore in Q1 FY27. That is ₹576 crore over the four quarters. Revenue from operations: ₹550 crore, ₹423 crore, ₹611 crore and ₹418 crore.

What was Anthem Biosciences' net profit in FY26?

Consolidated net profit was ₹592 crore in FY26 (April 2025–March 2026).

What was Anthem Biosciences' revenue in FY26?

Revenue from operations was ₹2,124 crore in FY26 (April 2025–March 2026).

Where do these Anthem Biosciences figures come from?

From Anthem Biosciences' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.